ISOFORMIX INC.

Sugar Land, TX · Biotech · Private

Mass spectrometry immunoassay for detecting clusterin glycoforms as Alzheimer's disease biomarkers

Claim this profile

Follows are private to you and power your alerts

Updated · isoformix.com

Sector
Biotech
Headquarters
Sugar Land, TX
Total capital
$1.8M
Federal grants
$1.8M
7 awards · 2018–2023
Rank in peer group#2 of 26
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

201820192020202120222023FEDERAL ↑EQUITY ↓Cumulative $1.8M$154K$251K$251K$256K$385K$385K
201820192020202120222023FEDERAL ↑EQUITY ↓Cumulative $1.8M$251K$256K$385K$385K

Latest events

  • Federal grantHealth and Human S · Phase I · Clusterin glycosylation as diagnostic and prognostic biomarker for Alzheimer's disease$385K
  • Federal grantHealth and Human S · Phase I · Clusterin glycosylation as diagnostic and prognostic biomarker for Alzheimer's disease$385K
  • Federal grantHealth and Human S · Phase I · Immunoplate-MALDI MS platform and assays$256K
  • Federal grantHealth and Human S · Phase I · ApoE isoform-specific glycosylation as diagnostic and prognostic biomarker of Alzheimer's disease$251K
  • Federal grantHealth and Human S · Phase I · ApoE isoform-specific glycosylation as diagnostic and prognostic biomarker of Alzheimer's disease$251K
  • Federal grantHealth and Human S · Phase I · Clinical mass spectrometry test for apolipoprotein C-III proteoforms$154K
  • Federal grantHealth and Human S · Phase I · Clinical mass spectrometry test for apolipoprotein C-III proteoforms$154K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 26 peers

Line = median

Biotech · Instrument

  • Federal grants#2 · top 8%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • ORIGAMI THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
  • Claris BioSimilar federal contract value in Biotech · null in contracts
  • Haya TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • NewleosSimilar federal contract value in Biotech · null in contracts
  • ONCOBLAZE LLCSimilar federal contract value in Biotech · null in contracts
  • Gamow Labs, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .